Caring for the most fragile patients

More than one out of ten children are born preterm and they depend on neonatal intensive care for their survival.

Next generation neonatal care

Never before have we had so many babies born too soon. More than one out of ten new-born babies need neonatal care. Pulmonary complications are often the primary reason since the lungs of these babies are not yet fully developed. Today the lung status is mainly assessed by routine X-ray imaging and invasive blood sampling, despite the increased risks of long-term complications from ionizing radiation, blood loss, infection and pain.

We believe preterm born babies deserves a better start in life. That’s why we developed NEOLA® to monitor the lungs of these babies continuously. Based on an advanced spectroscopic technology for measurements of gas concentrations cavities, the device detects and instantly warns for possibly life-threatening pulmonary complications. Fast detection means early treatment by the neonatologist and better care for the baby.


Emilie Krite Svanberg, MD., PhD., and Dennis Leader, MSc, GPX Medical, during clinical pilot study on healthy newborn infants at Skåne University Hospital in the fall of 2018.


Many preterm born infants suffer from pulmonary complications for which an early detection is critical for good care. GPX Medical’s NEOLA® continuously measures lung volume and oxygen content in the lungs for an instant detection of complications such as atelectasis and pneumothorax, if the airways are obstructed or if the tracheal tube is misplaced.


How does it work?

• Near-infrared light is sent through the torso. A small portion is absorbed by water vapor and oxygen gas molecules in the lungs.
• The detector probe detects some of the light that travelled through the tissue.
• The signal shows how much of the light that has been absorbed by the gas molecules.
• The light is low power, eyesafe and does not induce heating.

Clinical Use
• The small and light-weight emitter and detector probes are positioned on the skin.
• Once positioned, NEOLA® will register small changes related
to lung volume and oxygen content.
• The probes are easily removed and re-positioned.

For Investors

GPX Medical is on a journey to create better care for for our most vulnerable patients.

About GPX Medical

GPX Medical AB was formed in 2016 as a subsidiary to Gasporox AB (publ) with the aim to develop and commercialize medical applications of the GASMAS technology. The company is owned by Gasporox AB (publ) to 53,3%, by Norsk Elektro Optikk AS to 36,2% and by the team to 10,5%. The company is located in Lund, Sweden. Org. nbr. 559069-9012.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:


GPX Medical AB
Tellusgatan 13
224 57 Lund